Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2016-02-09 Earnings Release
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Fourth quarter and preliminary full year 2015 results
Earnings Release Classification · 99% confidence The document provides a detailed review of the company's performance for the 'FOURTH QUARTER 2015' and 'FY 2015', including a financial review with comparative figures for Q4 2014 and FY 2014. It contains a CEO statement, operational highlights, a condensed interim consolidated financial information section (Profit and Loss, Balance Sheet data implied by cash flow/balance sheet review), and an outlook. The content is comprehensive for a specific reporting period shorter than a full year (Q4), but it is not the full annual report (10-K). The presence of 'Q4 2015' results and the structure strongly suggest a periodic financial report covering less than 12 months. Since it is a comprehensive report for a period shorter than a year, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an Earnings Release (ER) as it contains detailed financial tables and operational reviews, nor is it a Management Discussion and Analysis (MDA) as the financial statements are central. Q4 2015
2016-02-09 English
PCI Biotech: Fourth quarter and preliminary full year 2015 results
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Q4 2015 PRESENTATION' and contains financial highlights for Q4 2015, clinical trial updates, research collaboration details, and key financial figures comparing Q4 2015 to Q4 2014. This structure—a presentation summarizing period results, strategy, and pipeline—is characteristic of an Investor Presentation (IP), often used in conjunction with or immediately following an Earnings Release (ER). Since it is a detailed presentation format rather than just the initial press release highlights (ER) or a comprehensive statutory report (10-K/IR), Investor Presentation (IP) is the most appropriate classification. The length (16,875 chars) confirms it is a substantial document, not a brief announcement (RPA/RNS).
2016-02-09 English
PCI Biotech: Fourth quarter and preliminary full year 2015 results
Report Publication Announcement Classification · 98% confidence The document explicitly states it contains the 'financial report and presentation for fourth quarter 2015' and announces a presentation event. The document itself is very short (807 characters) and serves primarily to announce the availability of the results and the associated presentation event, rather than being the full financial report (IR or 10-K) or the presentation itself (IP). This fits the definition of a Report Publication Announcement (RPA), which signals the release of other documents.
2016-02-09 English
PCI Biotech: Invitation to fourth quarter and preliminary full year 2015 presentation
Report Publication Announcement Classification · 95% confidence The document is an invitation to a presentation covering the fourth quarter and preliminary full year 2015 results, scheduled for February 9, 2016. It is not the full report itself, nor is it a transcript of the call. It is an announcement about an upcoming event where financial results will be discussed. This fits best under the category of an announcement regarding the publication or presentation of financial results, which aligns with 'Report Publication Announcement' (RPA), as it announces the presentation of the Q4/FY preliminary results.
2016-02-02 English
PCI Biotech and Ultimovacs initiates preclinical research collaboration
M&A Activity Classification · 99% confidence The document announces a preclinical research collaboration between two biopharmaceutical companies, PCI Biotech and Ultimovacs. It details the purpose, agreement terms, and includes quotes from the CEOs. This type of announcement, detailing a strategic business development or partnership, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR, CAP, etc.). Since it is a formal announcement of a business event that is not a standard regulatory filing like a director's dealing or major shareholding change, and it is not a presentation (IP) or a transcript (CT), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate announcements that are material but don't fit other specific codes.
2016-01-27 English
PCI Biotech: Dose escalation in the bile duct cancer study completed with promising early signs of efficacy
Earnings Release Classification · 99% confidence The document is a press release from PCI Biotech dated January 22, 2016, announcing the completion of a dose escalation cohort in a Phase I/II clinical study for bile duct cancer and the recommendation to proceed to Phase II based on promising early efficacy signs. This type of announcement, detailing clinical trial progress, safety data review, and next steps (like protocol amendments and regulatory approval timelines), is characteristic of an update on ongoing research and development activities. It is not a full Annual Report (10-K), a formal Audit Report (AR), a formal Earnings Release (ER) focusing on financial performance, or a formal Investor Presentation (IP). It is a specific operational update. Given the options, this is best classified as a general announcement related to company operations and progress, which often falls under Regulatory Filings (RNS) if no other specific category fits perfectly. However, since it details clinical trial progress and scientific milestones, it is a significant piece of investor information. It is not a management discussion (MDA), a capital event (CAP), or a director dealing (DIRS). Since it is a news release about clinical progress, and not a formal financial report, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate general category for non-standard operational news releases, although it could also be argued as a type of Investor Information. Given the specific definitions, RNS serves as the best fit for this type of operational/clinical update press release that isn't explicitly covered by ER, IR, or MDA. Q1 2016
2016-01-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.